BUFFALO, N.Y. - University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing ...

Cybin (CYBN) announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in ...

Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

has reported promising results from its Phase 2 study of CYB003, showing significant long-term efficacy in treating major depressive disorder with 100% of participants responding to treatment and 71% ...

Cybin has reported 71% remission in patients with major depressive disorder (MDD) who received two doses of the psilocin ...